AG真人官方

STOCK TITAN
  1. Home
  2. Sec-filings
  3. RVMD
  4. [Form 4] Revolution Medicines, Inc. Insider Trading Activity

[Form 4] Revolution Medicines, Inc. Insider Trading Activity

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

Revolution Medicines (RVMD) General Counsel Jeff Cislini reported a sale of 1,912 shares of common stock on June 20, 2025, at a weighted average price of $39.61 per share (range: $39.26-$40.05). The transaction was executed under a pre-established 10b5-1 trading plan adopted on March 13, 2025.

Following the transaction, Cislini retains beneficial ownership of 54,093 shares, including 49,054 restricted stock units. The sale was reported through Form 4 filed on June 28, 2025, and was executed in compliance with SEC regulations. The transaction was filed by Cislini's attorney-in-fact, Jack Anders.

Revolution Medicines (RVMD) Il Consulente Legale Generale Jeff Cislini ha comunicato la vendita di 1.912 azioni ordinarie il 20 giugno 2025, ad un prezzo medio ponderato di 39,61$ per azione (intervallo: 39,26$-40,05$). La transazione 猫 stata eseguita secondo un piano di trading 10b5-1 predefinito adottato il 13 marzo 2025.

Dopo l鈥檕perazione, Cislini mantiene la propriet脿 effettiva di 54.093 azioni, comprendenti 49.054 unit脿 di azioni vincolate. La vendita 猫 stata segnalata tramite il Modulo 4 depositato il 28 giugno 2025 ed 猫 stata effettuata nel rispetto delle normative SEC. La transazione 猫 stata presentata dall鈥檃vvocato di fiducia di Cislini, Jack Anders.

Revolution Medicines (RVMD) El Asesor Jur铆dico General Jeff Cislini inform贸 la venta de 1,912 acciones comunes el 20 de junio de 2025, a un precio promedio ponderado de $39.61 por acci贸n (rango: $39.26-$40.05). La transacci贸n se realiz贸 bajo un plan de trading 10b5-1 preestablecido adoptado el 13 de marzo de 2025.

Tras la operaci贸n, Cislini conserva la propiedad beneficiaria de 54,093 acciones, incluyendo 49,054 unidades restringidas de acciones. La venta fue reportada mediante el Formulario 4 presentado el 28 de junio de 2025 y se ejecut贸 conforme a las regulaciones de la SEC. La transacci贸n fue presentada por el apoderado legal de Cislini, Jack Anders.

Revolution Medicines (RVMD) 氩曤 瓿犽 鞝滍攧 鞁滌姮毽媹電� 2025雲� 6鞗� 20鞚检棎 1,912欤�鞚� 氤错喌欤茧ゼ 欤茧嫻 臧�欷� 韽夑窢 臧�瓴� $39.61(氩旍渼: $39.26-$40.05)鞐� 韺愲Г頄堧嫟瓿� 氤搓碃頄堨姷雼堧嫟. 鞚� 瓯半灅電� 2025雲� 3鞗� 13鞚� 毂勴儩霅� 靷爠 靹れ爼霅� 10b5-1 瓯半灅 瓿勴殟鞐� 霐半澕 鞚措（鞏挫鞀惦媹雼�.

瓯半灅 頉� 鞁滌姮毽媹電� 49,054臧滌潣 鞝滍暅 欤检嫕 雼渼毳� 韽暔頃橃棳 齑� 54,093欤�鞚� 鞁れ 靻岇湢甓岇潉 氤挫湢頃橁碃 鞛堨姷雼堧嫟. 鞚措矆 毵る弰電� 2025雲� 6鞗� 28鞚检棎 鞝滌稖霅� Form 4毳� 韱淀暣 氤搓碃霅橃棃鞙茧┌, SEC 攴滌爼鞚� 欷�靾橅晿鞐� 鞁ろ枆霅橃棃鞀惦媹雼�. 鞚� 瓯半灅電� 鞁滌姮毽媹鞚� 氩曤 雽�毽澑 鞛� 鞎る崝鞀り皜 鞝滌稖頄堨姷雼堧嫟.

Revolution Medicines (RVMD) Le conseiller juridique g茅n茅ral Jeff Cislini a d茅clar茅 la vente de 1 912 actions ordinaires le 20 juin 2025, 脿 un prix moyen pond茅r茅 de 39,61 $ par action (fourchette : 39,26 $ - 40,05 $). La transaction a 茅t茅 r茅alis茅e dans le cadre d鈥檜n plan de n茅gociation 10b5-1 pr茅茅tabli adopt茅 le 13 mars 2025.

Apr猫s la transaction, Cislini conserve la propri茅t茅 b茅n茅ficiaire de 54 093 actions, dont 49 054 unit茅s d鈥檃ctions restreintes. La vente a 茅t茅 rapport茅e via le formulaire 4 d茅pos茅 le 28 juin 2025 et a 茅t茅 ex茅cut茅e conform茅ment aux r茅glementations de la SEC. La transaction a 茅t茅 d茅pos茅e par le mandataire de Cislini, Jack Anders.

Revolution Medicines (RVMD) General Counsel Jeff Cislini meldete den Verkauf von 1.912 Aktien des Stammkapitals am 20. Juni 2025 zu einem gewichteten Durchschnittspreis von 39,61 $ pro Aktie (Spanne: 39,26 $-40,05 $). Die Transaktion wurde im Rahmen eines vorab festgelegten 10b5-1-Handelsplans durchgef眉hrt, der am 13. M盲rz 2025 angenommen wurde.

Nach der Transaktion beh盲lt Cislini das wirtschaftliche Eigentum an 54.093 Aktien, darunter 49.054 beschr盲nkte Aktieneinheiten. Der Verkauf wurde durch das am 28. Juni 2025 eingereichte Formular 4 gemeldet und erfolgte in 脺bereinstimmung mit den SEC-Vorschriften. Die Transaktion wurde von Cislini鈥檚 bevollm盲chtigtem Vertreter Jack Anders eingereicht.

Positive
  • None.
Negative
  • None.

Revolution Medicines (RVMD) Il Consulente Legale Generale Jeff Cislini ha comunicato la vendita di 1.912 azioni ordinarie il 20 giugno 2025, ad un prezzo medio ponderato di 39,61$ per azione (intervallo: 39,26$-40,05$). La transazione 猫 stata eseguita secondo un piano di trading 10b5-1 predefinito adottato il 13 marzo 2025.

Dopo l鈥檕perazione, Cislini mantiene la propriet脿 effettiva di 54.093 azioni, comprendenti 49.054 unit脿 di azioni vincolate. La vendita 猫 stata segnalata tramite il Modulo 4 depositato il 28 giugno 2025 ed 猫 stata effettuata nel rispetto delle normative SEC. La transazione 猫 stata presentata dall鈥檃vvocato di fiducia di Cislini, Jack Anders.

Revolution Medicines (RVMD) El Asesor Jur铆dico General Jeff Cislini inform贸 la venta de 1,912 acciones comunes el 20 de junio de 2025, a un precio promedio ponderado de $39.61 por acci贸n (rango: $39.26-$40.05). La transacci贸n se realiz贸 bajo un plan de trading 10b5-1 preestablecido adoptado el 13 de marzo de 2025.

Tras la operaci贸n, Cislini conserva la propiedad beneficiaria de 54,093 acciones, incluyendo 49,054 unidades restringidas de acciones. La venta fue reportada mediante el Formulario 4 presentado el 28 de junio de 2025 y se ejecut贸 conforme a las regulaciones de la SEC. La transacci贸n fue presentada por el apoderado legal de Cislini, Jack Anders.

Revolution Medicines (RVMD) 氩曤 瓿犽 鞝滍攧 鞁滌姮毽媹電� 2025雲� 6鞗� 20鞚检棎 1,912欤�鞚� 氤错喌欤茧ゼ 欤茧嫻 臧�欷� 韽夑窢 臧�瓴� $39.61(氩旍渼: $39.26-$40.05)鞐� 韺愲Г頄堧嫟瓿� 氤搓碃頄堨姷雼堧嫟. 鞚� 瓯半灅電� 2025雲� 3鞗� 13鞚� 毂勴儩霅� 靷爠 靹れ爼霅� 10b5-1 瓯半灅 瓿勴殟鞐� 霐半澕 鞚措（鞏挫鞀惦媹雼�.

瓯半灅 頉� 鞁滌姮毽媹電� 49,054臧滌潣 鞝滍暅 欤检嫕 雼渼毳� 韽暔頃橃棳 齑� 54,093欤�鞚� 鞁れ 靻岇湢甓岇潉 氤挫湢頃橁碃 鞛堨姷雼堧嫟. 鞚措矆 毵る弰電� 2025雲� 6鞗� 28鞚检棎 鞝滌稖霅� Form 4毳� 韱淀暣 氤搓碃霅橃棃鞙茧┌, SEC 攴滌爼鞚� 欷�靾橅晿鞐� 鞁ろ枆霅橃棃鞀惦媹雼�. 鞚� 瓯半灅電� 鞁滌姮毽媹鞚� 氩曤 雽�毽澑 鞛� 鞎る崝鞀り皜 鞝滌稖頄堨姷雼堧嫟.

Revolution Medicines (RVMD) Le conseiller juridique g茅n茅ral Jeff Cislini a d茅clar茅 la vente de 1 912 actions ordinaires le 20 juin 2025, 脿 un prix moyen pond茅r茅 de 39,61 $ par action (fourchette : 39,26 $ - 40,05 $). La transaction a 茅t茅 r茅alis茅e dans le cadre d鈥檜n plan de n茅gociation 10b5-1 pr茅茅tabli adopt茅 le 13 mars 2025.

Apr猫s la transaction, Cislini conserve la propri茅t茅 b茅n茅ficiaire de 54 093 actions, dont 49 054 unit茅s d鈥檃ctions restreintes. La vente a 茅t茅 rapport茅e via le formulaire 4 d茅pos茅 le 28 juin 2025 et a 茅t茅 ex茅cut茅e conform茅ment aux r茅glementations de la SEC. La transaction a 茅t茅 d茅pos茅e par le mandataire de Cislini, Jack Anders.

Revolution Medicines (RVMD) General Counsel Jeff Cislini meldete den Verkauf von 1.912 Aktien des Stammkapitals am 20. Juni 2025 zu einem gewichteten Durchschnittspreis von 39,61 $ pro Aktie (Spanne: 39,26 $-40,05 $). Die Transaktion wurde im Rahmen eines vorab festgelegten 10b5-1-Handelsplans durchgef眉hrt, der am 13. M盲rz 2025 angenommen wurde.

Nach der Transaktion beh盲lt Cislini das wirtschaftliche Eigentum an 54.093 Aktien, darunter 49.054 beschr盲nkte Aktieneinheiten. Der Verkauf wurde durch das am 28. Juni 2025 eingereichte Formular 4 gemeldet und erfolgte in 脺bereinstimmung mit den SEC-Vorschriften. Die Transaktion wurde von Cislini鈥檚 bevollm盲chtigtem Vertreter Jack Anders eingereicht.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
 Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Cislini Jeff
(Last) (First) (Middle)
C/O REVOLUTION MEDICINES, INC.
700 SAGINAW DRIVE
(Street)
REDWOOD CITY CA 94063
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Revolution Medicines, Inc. [ RVMD ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
General Counsel
3. Date of Earliest Transaction (Month/Day/Year)
06/20/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 06/20/2025 S(1) 1,912 D $39.6108(2) 54,093(3) D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 13, 2025.
2. This transaction was executed in multiple trades in prices ranging from $39.26 to $40.05, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
3. Includes 49,054 restricted stock units.
/s/ Jack Anders, as Attorney-in-fact for Jeff Cislini 06/23/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source:

FAQ

How many shares of RVMD stock did General Counsel Jeff Cislini sell on June 20, 2025?

Jeff Cislini sold 1,912 shares of RVMD common stock on June 20, 2025, at a weighted average price of $39.6108 per share.

What was the price range of RVMD shares sold in the insider transaction on June 20, 2025?

The shares were sold in multiple trades with prices ranging from $39.26 to $40.05 per share, with a weighted average sale price of $39.6108.

How many RVMD shares does Jeff Cislini own after the June 20, 2025 transaction?

Following the reported transaction, Jeff Cislini beneficially owns 54,093 shares, which includes 49,054 restricted stock units (RSUs).

Was RVMD General Counsel's stock sale part of a pre-planned trading arrangement?

Yes, the transaction was made pursuant to a Rule 10b5-1 trading plan that was adopted by Jeff Cislini on March 13, 2025.
Stock RVMD logo
Revolution Medicines, Inc.

NASDAQ:RVMD

RVMD Rankings

#1508 Ranked by Market Cap
N/A Ranked by Dividends

RVMD Latest News

Jul 24, 2025
Revolution Medicines Announces Publication of a Peer-Reviewed Research Paper in Science on the Discovery and Development of Zoldonrasib, a RAS(ON) G12D-Selective Inhibitor
Jul 23, 2025
Revolution Medicines Announces FDA Breakthrough Therapy Designation for Elironrasib
Jul 9, 2025
Revolution Medicines and Iambic Announce Technology and Research Collaboration Using Iambic鈥檚 AI Discovery Tools to Pursue New Drug Candidates
Jun 30, 2025
Revolution Medicines and Summit Therapeutics Enter into Clinical Collaboration to Evaluate Combinations of Three RAS(ON) Inhibitors with Ivonescimab in RAS Mutant Tumors
Jun 24, 2025
Revolution Medicines Enters Into $2 Billion Flexible Funding Agreement with Royalty Pharma to Support Global Development and Commercialization of RAS(ON) Inhibitor Portfolio for Patients with RAS-Addicted Cancers

RVMD Latest SEC Filings

Jul 2, 2025
[Form 4] Revolution Medicines, Inc. Insider Trading Activity
Jun 30, 2025
[Form 4] Revolution Medicines, Inc. Insider Trading Activity
Jun 30, 2025
[Form 4] Revolution Medicines, Inc. Insider Trading Activity
Jun 30, 2025
[Form 4] Revolution Medicines, Inc. Insider Trading Activity
Jun 30, 2025
[Form 4] Revolution Medicines, Inc. Insider Trading Activity

RVMD Stock Data

6.99B
181.47M
2.06%
106.38%
8.52%
Biotechnology
Biological Products, (no Disgnostic Substances)
United States
REDWOOD CITY